Table of Contents
nse: wockpharma is a global pharmaceutical and biotechnology company providing high-quality, affordable medicines for a healthier world. It is India’s leading research-based global healthcare company with relevance in pharmaceuticals, biotechnology, and a chain of advanced super-specialty hospitals.
It is an authentic Indian multinational with a multi-ethnic workforce consisting of many Wockhardt employees of many different nationalities across the globe. Also, it has many research centers and multiple manufacturing facilities with businesses.
nse: wockpharma ranges from manufacturing and marketing pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines. It is a business in transition, and new and innovative business models are underway to make the most of the opportunities that arise.
A new drive for growth permeates every way of thinking, every process, and every technological innovation at Wockhardt today.
NSE: WOCKPHARMA Stock Overview
nse: wockpharma is a pharmaceutical and biotechnology company that manufactures and markets active pharmaceutical ingredients. In addition, it formulates formulations, biosimilars, and vaccines in India, the United States, the United Kingdom, Ireland, Mexico, Russia and internationally.
nse: wockpharma is a global biotechnology and pharmaceutical company headquartered in Mumbai, India. It produces formulations, biopharmaceuticals, nutritional products, vaccines, and active pharmaceutical ingredients (APIs).
The Company has manufacturing facilities in India, the UK, Ireland, France and the US and subsidiaries in the US, UK, Ireland and France.
NSE: WockPharma History
Wockpharma was founded in the 1960s by Dr. Founded Habil Khorakiwala. His father, Fakhruddin T. Khorakiwala, took over Worli Chemical Works in 1959. This was founded in 1973 as Wockhardt Pvt. ltd founded. wockhardt ltd was founded on February 8, 1999.
In the 1990s, Wockhardt gained market share with its pain reliever Proxyvon (opioid tramadol + paracetamol) and antihypertensive drugs. In 1995, it expanded into biotechnology and then began producing intravenous fluids.
Wockhardt is the first Company outside of the US and Europe to manufacture recombinant human insulin.
In 2011, Wockhardt sold his nutrition business to Danone for $356 million.
During the COVID-19 pandemic, Wockhardt signed a deal with the UK Government to complete and finalize the Oxford-AstraZeneca COVID-19 vaccine at the Company’s facility in Wrexham, Wales. The contract was extended until August 2022.
In August 2021, Wockhardt announced that he had signed an agreement with Dubai-based Enso Healthcare and Russian company Human Vaccine LLC to commission the manufacturing of the Sputnik V and Sputnik Light vaccines in India.
More About WOCKPHARMA
Wockpharma Limited is a pharmaceutical and biotechnology company. Also, the Company’s businesses include manufacturing and marketing pharmaceutical and biopharmaceutical formulations, active pharmaceutical ingredients (APIs), and vaccines.
Manufacturers have a variety of dosage forms, including sterile injection and lyophilized products.
The Company offers products in the therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough management, and diabetology.
The Company’s products in India include Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, and DARBOTIN PFS.
Also, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450.
The Company has approximately three research centers worldwide and a chain of six super specialty hospitals in Maharashtra and Gujarat.
Traded Volume (Shares) 4,67,263
Traded Value (₹ Lakhs) 800.56
Total Market Cap (₹ Lakhs) 2,44,013.58
Free Float Market Cap (₹ Lakhs) 95,530.56
Impact cost 0.08
52 Week High (18-Apr-2022) 298.00
52 Week Low (29-Mar-2023) 145.15
Upper Band 208.85
Lower Band 139.25
Price Band 20
Value at Risk (%) [Updated intra-day]
Security VaR 16.88
Index VaR –
VaR Margin 16.88
Extreme Loss Rate 3.50
Adhoc Margin 14.62
Applicable Margin Rate 35.00
NSE: Wockpharma Stock Price Analysis And Quick Research Report
India’s healthcare sector is expected to reach US$372 billion by 2022, driven by rising incomes, increased health awareness, lifestyle-related diseases, and better access to health insurance.
Healthcare is one of the largest sectors in India, both in terms of revenue and employment.
Healthcare includes hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the health care system in India consists of three major segments: primary care, secondary care, and tertiary care.
Primary health care is the first point of contact between the population and healthcare providers.
For example, Subcentro (SC), Primary Health Center (PHC), and Community Health Center (CHC), which is more relevant to rural areas (PHC)
Secondary providers of inpatient and outpatient medical services and includes simple surgical procedures. For example, district-level hospitals and medium-sized hospitals.
Tertiary care is the third tier of the country’s health care system. Also, these hospitals are a healthcare infrastructure for specialized advice. For example, hospitals with one or more specialties.
Although healthcare services are provided by both public and private sectors in both urban and rural areas.
Is Wockpharma An Attractive Stock To Invest In?
People generally prefer private hospitals to public hospitals to treat diseases and ailments. So let’s take a look at Wockpharma and his performance over time.
Operating Cash Flow Ratio: Measures the adequacy of a company’s cash generated from operations to meet short-term financial obligations. Its cash from operations was Rs -93 Cr.
Financial Strength: Healthcare organizations typically have high debt levels and low equity levels on their balance sheets.
Therefore, the debt-to-capital ratio is essential to analyze the sustainability of the Company. Wockhardt has a gearing ratio of 0.72, a strong indicator for the Company.
EPS Growth – Investors should ensure that the EPS number is growing faster than the revenue numbers. It indicates that the Company’s management is increasing the efficiency with which they run the Company. At Wockhardt, EPS growth was 70.39%, which is suitable for the Company.
Operating Profit Margin: Determines a company’s earnings potential. When assessing how well a company is run regarding its essential overheads and other operating expenses, Wockhardt has an OPM of 16.18%, which bodes well for profitability.
ROE: Wockpharma has a low ROE of -7.42%. ROE is a significant financial metric for hospitals and healthcare companies as they expand and proliferate. Therefore, ROE measures how efficiently a shareholder’s capital is used to generate profits.
How Sales Coaching Can Improve Your Team
How Sales Coaching Can Improve Your Team Imagine a sales team that consistently meets its targets, communicates effectively, and retains…
Understanding the Benefits of Intelligent Search for Enterprise Businesses
Understanding the Benefits of Intelligent Search for Enterprise Businesses In today’s digital age, technology continues to evolve and redefine the…